• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients.
【24h】

Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients.

机译：可溶性MICA是多发性骨髓瘤患者总体生存和无进展生存的独立预后因素。

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Major histocompatibility complex class I-related chain A (MICA) molecules are frequently expressed in lymphoproliferative malignancies including multiple myeloma (MM). MICA activates NK cells and co-stimulates T cells by interaction with its immunoreceptor NKG2D. In contrast, soluble MICA (sMICA) molecules impair the functions of NKG2D(+) T and NK cells, which may facilitate tumor cell escape from immunosurveillance. Here, we analyzed the clinical relevance of sMICA in 97 MM patients. sMICA (mean+/-SEM pg/ml) was significantly increased (p<0.0001) in patients (429+/-20) compared to controls (230+/-20; N=43). Serial determination showed a strong correlation between increments of sMICA and paraprotein levels (r=0.543, p<0.0001, N=49). sMICA levels >305 pg/ml are associated with a poor overall (p=0.004) and progression-free survival (p=0.002). Multivariate analysis revealed sMICA as an independent predictive factor for overall (p=0.007) and progression-free survival (p=0.002). Thus, our results suggest sMICA as a potent prognostic marker in MM, which may be useful to identify risk patients.
机译：主要的组织相容性复杂的I类相关链A（MICA）分子经常在包括多发性骨髓瘤（MM）在内的淋巴增生性恶性肿瘤中表达。 MICA通过与其免疫受体NKG2D的相互作用激活NK细胞并共同刺激T细胞。相比之下，可溶性MICA（sMICA）分子会损害NKG2D（+）T和NK细胞的功能，这可能有助于肿瘤细胞逃避免疫监视。在这里，我们分析了sMICA在97 MM患者中的临床相关性。与对照组（230 +/- 20; N = 43）相比，患者（429 +/- 20）的sMICA（平均值+/- SEM pg / ml）显着增加（p <0.0001）。连续测定显示sMICA的增加与副蛋白水平之间有很强的相关性（r = 0.543，p <0.0001，N = 49）。 sMICA水平> 305 pg / ml与总体不良（p = 0.004）和无进展生存期（p = 0.002）相关。多变量分析显示，sMICA是总体（p = 0.007）和无进展生存期（p = 0.002）的独立预测因子。因此，我们的研究结果提示sMICA作为MM的有效预后标志物，对识别危险患者可能有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号